PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 1, 20260 citationsOpen Access

CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND RT-qPCR FOR MOLECULAR TYPING OF FEMALE BREAST CANCER IN BOUAKE

View Full Paper
FYFaїza Alassani*1,2, Ibrahiman Touré1,3, Vincent Yapo4,5, Yaya Samaké1,6, Issouf Bamba4, Sarhatou Kamara7, Juste Dimitri Blidieu4, Dagoun Elysée Boko1,6, Lazare Touré1,8, Darya Kizub9, Atta Ange Rebecca Kobenan1,3, Kouamé Justin N'dah1,3, Gnangoran Victor Yao1,2

Key Points

  • The study aims to determine the concordance rate between immunohistochemistry (IHC) and RT-qPCR for molecular typing of breast cancer.
  • Prospective descriptive cross-sectional study design
  • Analyzed expression of ER1, PR, and HER2 genes
  • Utilized fresh biopsy samples from breast cancer patients
  • Conducted in Bouaké over a 16-month period
  • 69.8% of patients had hormone-sensitive cancers
  • 44.2% had luminal A subtype and 25.6% had luminal B subtype
  • The mean age of participants was 43.8 years
  • Cohen's κ coefficient of concordance was 0.86 for ER1, 0.64 for PR, and 0.79 for HER2

Abstract

Background: Immunohistochemistry is a technique commonly used in the diagnosis of breast cancer. It is performed on histological preparations, following conventional histological examination. This lengthens the time it takes for patients to receive their results. RT-qPCR has been proposed as an alternative for shorter turnaround times compatible with early management. Objective: In the present study the aim was to determine the concordance rate between immunohistochemistry and RT-qPCR analyses on fresh biopsy samples from breast cancer patients in Bouaké. Methods: Studies on this subject have analyzed frozen paraffin blocks. This prospective descriptive cross-sectional study analyzed the expression of estrogen receptor α (ER1), progesterone receptor (PR) and human epidermal growth factor β (HER2) genes by immunohistochemistry and RT-qPCR. It took place over a 16-month period (September 2023-January 2025). Patients came from the 5 diagnostic and management centers for breast pathologies in the Gbêkê region. Results: The mean age was 43.8 ± 11.0 years, with extremes of 24 and 71 years. More than two-thirds of patients (69.8%) had hormone-sensitive cancer, with a preponderance of luminal A (44.2%) followed by luminal B (25.6%). The estrogen receptor gene (ER1) was overexpressed in 44.2% of carcinogenic breast biopsies. PR and HER2 genes expression was elevated in 53.5% and 34.9% of cases respectively. Cohen's κ coefficient of concordance between IHC and RT-qPCR was 0.86, 0.64 and 0.79 for ER1, PR and HER2 respectively. Conclusion : Determining gene expression by RT-qPCR on fresh biopsies could prove useful for rapid and efficient patient management.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Faїza Alassani*1,2, Ibrahiman Touré1,3, Vincent Yapo4,5, Yaya Samaké1,6, Issouf Bamba4, Sarhatou Kamara7, Juste Dimitri Blidieu4, Dagoun Elysée Boko1,6, Lazare Touré1,8, Darya Kizub9, Atta Ange Rebecca Kobenan1,3, Kouamé Justin N'dah1,3, Gnangoran Victor Yao1,2 (2026) studied this question.

synapsesocial.com/papers/69a3d8caec16d51705d30021https://doi.org/10.5281/zenodo.18795886
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Concordance between ER, PR, Ki67, and HER2‐low expression in breast cancer by MammaTyper RT‐qPCR and immunohistochemistry: implications for the practising pathologist2024 · 14 citations
  2. 2Abstract PO2-14-05: COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER2024
  3. 3Comparative Evaluation of HER2 Overexpression in Breast Carcinoma Using Cell Blocks and Corresponding Formalin-Fixed Paraffin-Embedded Tissue Blocks: A Prospective Study2026
  4. 4Agreement between incisional and excisional biopsies for hormone receptors and her2 in breast cancer2024 · 1 citations
  5. 5Analysis of the Clinical Value of Immunohistochemical Testing in the Pathological Diagnosis of Breast Cancer2024